COVID-19 vaccine candidates at Britain’s Oxford University and U. S. pharma company Pfizer each show promise, according to new results reported Monday.
July 20 (UPI) –COVID-19 vaccine candidates at Britain’s Oxford University and U. S. pharma company Pfizer each show promise, according to new results reported Monday.
Oxford and its partner, European drug maker AstraZenaca, released data in the medical journal The Lancet showing a strong immune response in a large, early-stage human trial.
Researchers said their candidate, ChAdOx1 nCoV-19, shows an “acceptable safety profile” and “homologous boosting increased antibody responses.”
Neutralizing antibodies that target the coronavirus that causes COVID-19 were detected in 91% of the trial’s 35 participants after a single dose, they added, and the antibodies were still present after 28 days.
